[Update 7/29/16: Bioventus is reported to have delayed its IPO. No additional information is available.]
Original, published 7/1/16: Bioventus registered for an initial public offering that it plans to use to pay off debt. The IPO registration put a placeholder amount of US $150MM, but that number is likely to change when Bioventus prices the flotation.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.
The business has grown since the spinout, which in 2010 reported $44MM in profits on $223MM in sales. For 2013, 2014 and 2015, the company reported revenue of $232.4MM, $242.9MM and $253.7MM, respectively.
Bioventus introduced two new products at this year’s AAOS and acquired BioStructures in 4Q15. In 4Q14, Bioventus acquired the OsteoAMP product line from Advanced Biologics.
Original, published 7/1/16: Bioventus registered for an initial public offering that it plans to use to pay off debt. The IPO registration put a placeholder amount of US $150MM, but that number is likely to change when Bioventus prices the flotation.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical...
[Update 7/29/16: Bioventus is reported to have delayed its IPO. No additional information is available.]
Original, published 7/1/16: Bioventus registered for an initial public offering that it plans to use to pay off debt. The IPO registration put a placeholder amount of US $150MM, but that number is likely to change when Bioventus prices the flotation.
Bioventus formed in 2012 when Smith & Nephew spun out its biologics and clinical therapies division in a joint venture with Essex Woodlands, a venture capital firm.
The business has grown since the spinout, which in 2010 reported $44MM in profits on $223MM in sales. For 2013, 2014 and 2015, the company reported revenue of $232.4MM, $242.9MM and $253.7MM, respectively.
Bioventus introduced two new products at this year’s AAOS and acquired BioStructures in 4Q15. In 4Q14, Bioventus acquired the OsteoAMP product line from Advanced Biologics.
Copy to clipboard 
